{
  "query": "Intellectual Property Litigation",
  "date": "2025-07-26T11:08:15.607212",
  "articles": [
    {
      "source": "The Verge",
      "author": "Mia Sato",
      "title": "Knock it off!",
      "description": "Cassey Ho was getting her roots dyed when she started receiving hundreds of ecstatic messages. In a video clip promoting her song “Fortnight,” Taylor Swift was shown wearing the Pirouette Skort, a flouncy, tutu-style skirt with built-in shorts underneath, tha…",
      "url": "https://www.theverge.com/cs/features/709635/knock-it-off",
      "urlToImage": "https://platform.theverge.com/wp-content/uploads/sites/2/2025/07/VERGE_FINAL1-1.gif?quality=90&strip=all&crop=0%2C10.732984293194%2C100%2C78.534031413613&w=1200",
      "publishedAt": "2025-07-22T12:04:03Z",
      "content": "Cassey Ho was getting her roots dyed when she started receiving hundreds of ecstatic messages. In a video clip promoting her song “Fortnight,” Taylor Swift was shown wearing the Pirouette Skort, a fl… [+38694 chars]"
    },
    {
      "source": "Windows Central",
      "author": "Jennifer Young",
      "title": "Nintendo is taking desperate measures in patent infringement case against Palworld — and it's looking a little weird",
      "description": "Nintendo’s legal campaign against Palworld continues with Pocketpair making gameplay changes to dodge infringement claims. Now Nintendo is rewriting its own patents mid-lawsuit — a move experts say looks like a last-ditch effort.",
      "url": "https://www.windowscentral.com/gaming/nintendo-is-taking-desperate-measures-in-patent-infringement-case-against-palworld-and-its-looking-a-little-weird",
      "urlToImage": "https://cdn.mos.cms.futurecdn.net/ehrBHKXifFQ469VGHMhJfi.jpg",
      "publishedAt": "2025-07-16T21:30:00Z",
      "content": "It's been pretty quiet on the news front in the ongoing battle between Nintendo and PocketPair over alleged patent infringement in Palworld. However, while the mainstream audience awaits a final verd… [+4594 chars]"
    },
    {
      "source": "Photorumors.com",
      "author": "PR admin",
      "title": "Insta360 responds to GoPro’s patent infringement allegations",
      "description": "A week ago, the International Trade Commission ruled that Insta360 infringed on GoPro's HERO camera design patent. A few days later, Insta360 responded that the International Trade Commission (ITC) has rejected GoPro's utility patent claims against Insta360. …",
      "url": "https://photorumors.com/2025/07/20/insta360-responds-to-gopros-patent-infringement-allegations/",
      "urlToImage": "https://photorumors.com/wp-content/uploads/2022/03/Insta360-camera-logo.jpg",
      "publishedAt": "2025-07-20T15:36:00Z",
      "content": "A week ago, the International Trade Commission ruled that Insta360 infringed on GoPro's HERO camera design patent. A few days later, Insta360 responded that the International Trade Commission (ITC) h… [+4183 chars]"
    },
    {
      "source": "Fstoppers",
      "author": "Alex Cooke",
      "title": "5 Camera Brands That Died Because They Couldn't Adapt",
      "description": "The photography industry witnessed one of business history's most dramatic upheavals during the digital revolution. Companies that dominated film photography for generations found themselves unprepared for fundamental changes in how images were captured, proc…",
      "url": "https://fstoppers.com/historical/5-camera-brands-died-because-they-couldnt-adapt-706230",
      "urlToImage": "https://cdn.fstoppers.com/styles/large-16-9/s3/lead/2025/07/asahi_pentax_s3_with_film.jpg",
      "publishedAt": "2025-07-12T20:03:01Z",
      "content": "The photography industry witnessed one of business history's most dramatic upheavals during the digital revolution. Companies that dominated film photography for generations found themselves unprepar… [+20624 chars]"
    },
    {
      "source": "IPWatchdog.com",
      "author": "Drew Berweger",
      "title": "Understanding IP Matters: Celebrated MIT Engineer and Entrepreneur Develops Medical Devices to Treat Cancer and Other Diseases",
      "description": "Universities have seen their role change since the Bayh-Dole Act was passed in 1980. They have been incentivized for both innovation and economic development, with patents being an important part of that landscape. With impending reductions in government fund…",
      "url": "https://ipwatchdog.com/2025/07/16/understanding-ip-matters-celebrated-mit-engineer-entrepreneur/id=190402/",
      "urlToImage": "https://ipwatchdog.com/wp-content/uploads/2025/07/Michael-Cima-11.jpg",
      "publishedAt": "2025-07-16T13:42:06Z",
      "content": "Universities have seen their role change since the Bayh-Dole Act was passed in 1980. They have been incentivized for both innovation and economic development, with patents being an important part of … [+3114 chars]"
    },
    {
      "source": "GlobeNewswire",
      "author": "Vicor Corporation",
      "title": "Vicor Corporation Reports Results for the Second Quarter Ended June 30, 2025",
      "description": "ANDOVER, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Vicor Corporation (NASDAQ: VICR) today reported financial results for the second quarter ended June 30, 2025. These results will be discussed later today at 5:00 p.m. Eastern Time, during management’s quarterl…",
      "url": "https://www.globenewswire.com/news-release/2025/07/22/3119824/0/en/Vicor-Corporation-Reports-Results-for-the-Second-Quarter-Ended-June-30-2025.html",
      "urlToImage": "https://ml.globenewswire.com/Resource/Download/55117480-366f-4254-a0c3-1c89d863eb54",
      "publishedAt": "2025-07-22T20:05:00Z",
      "content": "ANDOVER, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Vicor Corporation (NASDAQ: VICR) today reported financial results for the second quarter ended June 30, 2025. These results will be discussed later t… [+19037 chars]"
    },
    {
      "source": "Financial Post",
      "author": "GlobeNewswire",
      "title": "Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors",
      "description": "Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 App…",
      "url": "https://financialpost.com/globe-newswire/cabometyx-approved-in-the-eu-for-previously-treated-advanced-neuroendocrine-tumors",
      "urlToImage": null,
      "publishedAt": "2025-07-24T17:44:59Z",
      "content": "About Ipsen\r\nWe are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.\r\nOur pipeline… [+7602 chars]"
    },
    {
      "source": "GlobeNewswire",
      "author": "Purple Biotech Ltd.",
      "title": "Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025",
      "description": "REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.\r\n (\"Purple Biotech\" or \"the Company\") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, toda…",
      "url": "https://www.globenewswire.com/news-release/2025/07/23/3120090/0/en/Purple-Biotech-CEO-Issues-Letter-to-Shareholders-Highlighting-Pipeline-Progress-and-Clinical-Milestones-Achieved-in-First-Half-of-2025.html",
      "urlToImage": "https://ml.globenewswire.com/Resource/Download/4df18abe-32c5-403d-bdde-5871392e389d",
      "publishedAt": "2025-07-23T11:00:00Z",
      "content": "REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.\r\n (\"Purple Biotech\" or \"the Company\") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that see… [+10489 chars]"
    },
    {
      "source": "GlobeNewswire",
      "author": "Ipsen Pharma",
      "title": "Ipsen announces changes to its Executive Committee",
      "description": "PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:",
      "url": "https://www.globenewswire.com/news-release/2025/07/23/3119981/0/en/Ipsen-announces-changes-to-its-Executive-Committee.html",
      "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/81292fcc-6b3a-4e4a-a083-ea4191bf920a",
      "publishedAt": "2025-07-23T05:30:00Z",
      "content": "PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care biopharmaceutical company, today announced the following changes to its Executive Committee:\r\n<ul><li>Mari Sch… [+9398 chars]"
    },
    {
      "source": "GlobeNewswire",
      "author": "Ipsen Pharma",
      "title": "Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors",
      "description": "PARIS, FRANCE, 24 July 2025 - Ipsen announced today that the European Commission has approved Cabometyx® (cabozantinib) for adult patients with unresectable or metastatic, well differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumor…",
      "url": "https://www.globenewswire.com/news-release/2025/07/24/3121353/0/en/Cabometyx-approved-in-the-EU-for-previously-treated-advanced-neuroendocrine-tumors.html",
      "urlToImage": "https://ml-eu.globenewswire.com/Resource/Download/81292fcc-6b3a-4e4a-a083-ea4191bf920a",
      "publishedAt": "2025-07-24T17:41:00Z",
      "content": "<ul><li>Cabometyx® is the first and only systemic therapy to be approved in the European Union for previously treated unresectable or metastatic neuroendocrine tumors, regardless of tumor site, grade… [+15729 chars]"
    }
  ]
}